Haixin Zhihui Secures Series B2 Financing Within Three Months of Previous Round, Accelerating Development of AI-Powered Comprehensive Oncology Management Platform

On May 25, 2022, Zhejiang Haihui Technology Co., Ltd. (hereinafter referred to as “Haihui”), a leading intelligent service platform in China’s oncology diagnosis and treatment sector and a provider of whole-course disease management services for cancer patients, announced that it had secured additional Series B2 financing. The round saw follow-on investments from Tailong Investment, Xiamen Baotuo, and Zhenghe Benyuan. This marks Tailong Investment’s first investment in the oncology sector. ROBE CAPITAL served as the exclusive financial advisor.

The proceeds from this financing round will be used to further accelerate the development of our talent pipeline, strengthen the core team, recruit more senior industry professionals, continuously enhance our oncology intelligent services business line, and bolster R&D and commercial expansion.

It is worth noting that this marks the second financing round completed by Haihui this year. Leveraging its team’s strong execution capabilities, which have driven faster-than-expected growth, Haihui has achieved this milestone despite the current capital winter in the healthcare industry.In just three months, it secured two consecutive rounds of financing.

Founded in 2018, Haihui is an innovative technology company specializing in the oncology field, leveraging artificial intelligence to provide accessible disease management and services for patients. With the corporate mission of “Helping cancer patients live longer and better!”, it is committed to becoming the new infrastructure for future anti-cancer efforts.

Since its inception, Haihui Technology has made steady progress in the medical and life sciences sector, continuously driving innovation and upgrades while actively providing digital technology capabilities to the healthcare industry.To date, Haihui has expanded its reach to over 30 provinces and autonomous regions across China, covering more than 600 partner departments and serving tens of thousands of physicians. The number of registered patients has seen explosive growth, with hundreds of thousands proactively creating and real-time updating their disease progression records on the Haihui platform, leading to a geometric increase in user engagement.

While Haixin Zhihui's technological, product, and service capabilities are highly recognized within the industry,Over a three-month period, it also secured two consecutive rounds of financing.In February this year, Haihui Technology announced the completion of a B1 funding round worth hundreds of millions of yuan, led by Qiming Venture Partners. Recently, it also secured additional B2 round investments from Tigermed, Xiamen Baotuo, and Zhenghe Benyuan.

Currently, Haihui has successfully established an intelligent whole-course management platform for oncology. Its main product matrix and services include multi-cancer Clinical Decision Support Systems (CDSS), digital therapeutics, support for clinical new drug development, and out-of-hospital patient products and services.

There is a global emphasis on establishing a more modernized and standardized oncology diagnosis and treatment service system. Haihui’s CSCO AI Clinical Decision Support System, rooted in China, is an effective tool jointly developed by Chinese experts that aligns with the current treatment landscape for the Chinese population, representing a high-quality, standardized approach to oncology care.

CSCO AI is the only intelligent clinical decision support system officially named and endorsed by the Chinese Society of Clinical Oncology (CSCO). Jointly developed by CSCO and Haihui Technology, it assists clinicians in formulating more standardized and precise treatment plans. The system efficiently empowers oncology departments at all levels, elevating the overall standard of cancer diagnosis and treatment in China. It brings the oncology care capabilities of numerous departments up to CSCO standards, thereby enhancing the overall service capacity and efficiency of oncology units. Currently, products covering multiple cancer types—including breast cancer, lung cancer, esophageal cancer, gastric cancer, and colorectal cancer—have been launched, with full coverage across all cancer types expected within the next few years.

Haihui Technology, with a patient-centric approach, has established a comprehensive whole-course management system for oncology, developed diversified commercial service models, and supplemented these with multi-dimensional patient care, thereby enabling cancer patients to achieve genuine clinical benefits.

Haihui Technology adopts a patient-centric approach, creating an integrated management system that combines an intelligent engine with human case managers. This system covers the three major treatment scenarios—pre-hospital, in-hospital, and post-hospital—achieving closed-loop management of the entire disease course for patients both inside and outside the hospital. Leveraging its oncology patient database, Haihui Technology has built a diversified business service model, providing integrated oncology diagnosis and treatment solutions to government bodies, clinical trial recruitment services to pharmaceutical companies, and online marketplace services for out-of-hospital patient consumption to patients.

Meanwhile, Haihui Technology provides comprehensive patient care services. By focusing on patients’ mental health and establishing a large-scale community platform for real-world oncology peer support with hundreds of thousands of participants, the company delivers holistic patient care encompassing medical consultations, multidisciplinary consultations, health education, and peer-to-peer communication.

In the future, Haihui will consistently uphold its corporate mission of “helping cancer patients live longer and better,” continuously explore the application of innovative digital technologies throughout the entire course of oncology care, provide physicians with more robust technical and service support, deliver more comprehensive and high-quality services to patients, and accelerate the development of the oncology field.

Tailing Investment was established in 2021. The Taikun Fund, under its management, is a biomedical industry fund jointly initiated by Tigermed, Hangzhou State-owned Capital Investment and Operation Co., Ltd., Tailing Investment, and other partners, with a fund size of RMB 20 billion. The fund primarily invests in biomedicine, innovative medical devices, core CXO services and innovative sectors, as well as high-quality biomedical industry funds. It focuses on enterprises in innovative medical devices, biomedicine, healthcare services, healthcare informatics, digital therapeutics, intelligent manufacturing, and nutrition and health, covering all stages of corporate development.

Xiamen Baotuo Resources Co., Ltd., established in 2008, owns multiple wholly-owned subsidiaries located in the Xiamen Free Trade Zone, Hong Kong, Singapore, and other regions. With an annual turnover exceeding RMB 10 billion, its market presence extends across China, Japan, South Korea, Vietnam, India, Brazil, Mexico, Australia, the Netherlands, the United Kingdom, and other countries. Xiamen Baotuo has a broad investment portfolio spanning biopharmaceuticals, semiconductors, new materials, consumer goods, the automotive aftermarket, education, and SaaS. Zhejiang Haihui Technology Co., Ltd. is a landmark project marking Xiamen Baotuo’s entry into the biopharmaceutical investment sector.

ROBE CAPITAL, established in 2017, is a boutique investment bank specializing in healthcare and life sciences. Its business portfolio encompasses financial advisory, direct investment, industry consulting, and innovation incubation. The founding team hails from leading private equity firms, financial advisory institutions, management consulting companies, and vertical healthcare media outlets. Since its inception, ROBE CAPITAL has consistently completed double-digit private financing and M&A transactions annually, with a cumulative transaction value exceeding RMB 10 billion. In terms of value-added services for enterprises, the ROBE CAPITAL team boasts extensive industry expertise. In 2020, ROBE New Healthcare Fund was launched and has, to date, invested in more than ten leading companies within the sector.